The not-for-profit organization TB Alliance has announced the start of a clinical trial of a new regimen to treat extensively drug-resistant tuberculosis (XDR-TB.)
It is the first study to test an all-oral drug regimen, comprised of drugs with minimal pre-existing resistance, that has the potential to shorten, simplify, and improve treatment for XDR-TB, an airborne and infectious strain of tuberculosis that has resulted from progressive antibiotic resistance and is resistant to four commonly used anti-TB drugs. The trial will be carried out in South Africa where TB is prevalent. In a recent review of the experience in South Africa, after two years of treatment only 16% of people with XDR-TB were cured.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze